AI-generated analysis, not investment advice. The articles are written by AI, edited, and checked against company filings — but the judgements are opinions and the figures go stale. How this is made · Terms

⚠ Generic SubstitutionModerate threat

Abbott Laboratories (ABT) — threat to the moat

Abbott's branded generics compete against cheaper copies of the same molecules, and substitution rules favour the copy.

The branded generics business has one structural enemy: the cheaper copy. Abbott says "the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures"1.

Abbott Established Pharmaceuticals comparable growth, Q2 2026 (%)10.7Key Emerging Markets2.1OtherAbbott Q2 2026 earnings release, Established Pharmaceuticals sales table
The key markets grow five times faster.

Substitution happens when pharmacies or governments decide that a cheaper version is equivalent. As emerging-market health systems mature, they tend to adopt rules that favour the lowest-priced version, which is the opposite of what a brand needs.

So far the segment has grown through it. Key Emerging Markets sold $3,307 million in 20172 and $4,167 million in 20253, and grew 10.7% on a comparable basis in the second quarter of 20264.

The segment's smaller markets show the pressure first. Outside the Key Emerging Markets, sales grew 2.1% on a comparable basis in the second quarter5, against 10.7% in the key markets.

Little of the business is contracted. The segment's remaining performance obligations were $243 million at 30 June 20266, against sales of $5,536 million in 20257. Each pharmacy order is a fresh decision between the brand and the copy. The rest of the company has nothing like this exposure, because Abbott sells no branded generics in the United States8.

The early warning would be in the segment's smaller markets. Sales outside the Key Emerging Markets grew only 2.1% on a comparable basis in the second quarter9; if that turns negative while the Key Emerging Markets slow below 5%, substitution would be catching up with the brand.

References
  1. ReportedAbbott says "the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures".
    Abbott Laboratories Form 10-K for 2025 (year ended 31 December 2025) - Item 1A risk factors, competition, regulation and legal proceedings. — FY2025 · publ. 20 February 2026 · source ↗
  2. ReportedKey Emerging Markets sold $3,307 million in 2017 and $4,167 million in 2025, and grew 10.7% on a comparable basis in the second quarter of 2026.
    Abbott Laboratories Form 10-K for 2019 - the four reportable segments with Diabetes Care folded into Medical Devices from the fourth quarter of 2019 and 2017-2018 recast, product-line sales for 2017-2019, net earnings and EPS for 2017-2019 including the 2017 tax reform charge, and the balance sheet at 31 December 2019. — FY2019 · publ. February 2020 · source ↗
  3. ReportedKey Emerging Markets sold $3,307 million in 2017 and $4,167 million in 2025, and grew 10.7% on a comparable basis in the second quarter of 2026.
    Abbott Laboratories Form 10-K for 2025 (year ended 31 December 2025) - Item 1 and MD&A for Established Pharmaceutical Products and emerging markets. — FY2025 · publ. 20 February 2026 · source ↗
  4. ReportedKey Emerging Markets sold $3,307 million in 2017 and $4,167 million in 2025, and grew 10.7% on a comparable basis in the second quarter of 2026.
    Abbott Laboratories second-quarter 2026 earnings release, Form 8-K exhibit 99.1 - sales by segment and business, comparable growth, income statement, specified items, guidance and the 410th consecutive quarterly dividend - Established Pharmaceuticals sales and Key Emerging Markets. — Q2 2026 · publ. 16 July 2026 · source ↗
  5. ReportedOutside the Key Emerging Markets, sales grew 2.1% on a comparable basis in the second quarter, against 10.7% in the key markets.
    Abbott Laboratories second-quarter 2026 earnings release, Form 8-K exhibit 99.1 - sales by segment and business, comparable growth, income statement, specified items, guidance and the 410th consecutive quarterly dividend - Established Pharmaceuticals sales and Key Emerging Markets. — Q2 2026 · publ. 16 July 2026 · source ↗
  6. ReportedThe segment's remaining performance obligations were $243 million at 30 June 2026, against sales of $5,536 million in 2025.
    Abbott Laboratories Form 10-Q for the quarter ended 30 June 2026 - segment sales and operating earnings, the Exact Sciences acquisition and purchase-price allocation, the $20.0 billion of notes, remaining performance obligations, goodwill by segment, expected amortization, legal reserves and the NEC litigation, and the balance sheet at 30 June 2026 - Note 3 revenue: remaining performance obligations by segment and their timing. — Q2 2026 · publ. 28 July 2026 · source ↗
  7. ReportedThe segment's remaining performance obligations were $243 million at 30 June 2026, against sales of $5,536 million in 2025.
    Abbott Laboratories Form 10-K for 2025 (year ended 31 December 2025) - Item 1 business and the segment note: the four segments, sales and operating earnings, employees, manufacturing sites, customers and geography. — FY2025 · publ. 20 February 2026 · source ↗
  8. ReportedThe rest of the company has nothing like this exposure, because Abbott sells no branded generics in the United States.
    Abbott Laboratories second-quarter 2026 earnings release, Form 8-K exhibit 99.1 - sales by segment and business, comparable growth, income statement, specified items, guidance and the 410th consecutive quarterly dividend - total sales, income statement, specified items, tax rate, guidance and the dividend. — Q2 2026 · publ. 16 July 2026 · source ↗
  9. ReportedSales outside the Key Emerging Markets grew only 2.1% on a comparable basis in the second quarter; if that turns negative while the Key Emerging Markets slow below 5%, substitution would be catching up with the brand.
    Abbott Laboratories second-quarter 2026 earnings release, Form 8-K exhibit 99.1 - sales by segment and business, comparable growth, income statement, specified items, guidance and the 410th consecutive quarterly dividend - Established Pharmaceuticals sales and Key Emerging Markets. — Q2 2026 · publ. 16 July 2026 · source ↗
Sources
Generated October 6, 2026